Publikation
Individualized Treatment Approaches for Langerhans Cell Histiocytosis
Wissenschaftlicher Artikel/Review - 30.11.2017
Roider E, Dummer R, French L E, Cozzio Antonio, Hoetzenecker W, Jochum W, Balabanov S, Kerl K, Kamarachev J, Schaller M, Metzler G, Fehrenbacher B, Signer C, Guenova E
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Kurzbeschreibung/Zielsetzung
Langerhans cell histiocytosis (LCH) belongs to the rare histiocytic disorders, and has an estimated incidence of 1-2 cases per million adults [1]. Myeloid dendritic cells that express the same antigens (CD1a, CD207) as epidermal Langerhans cell seem to be the precursor cells for LCH [2]. Clinical presentation of patients with LCH may vary in site and extent of involvement. In 45% of patients LCH manifests as a multisystem disease including 77% bone, 39% skin, 19% lymph node, 16% liver, 13% spleen, 13% oral mucosa, 10% lung, and 6% CNS involvement [3]. This article is protected by copyright. All rights reserved.